Dyne Therapeutics Inc. (DYN) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Dyne Therapeutics Inc. (DYN:NASDAQ), powered by AI.

Current Price
$18.07
Sector
Healthcare
What is the Dyne Therapeutics Inc. stock price forecast?

Dyne Therapeutics Inc. is currently trading at $18.07. View real-time AI analysis on Alpha Lenz.

What is Dyne Therapeutics Inc. insider trading activity?

View the latest insider trading data for Dyne Therapeutics Inc. on Alpha Lenz.

What is Dyne Therapeutics Inc.'s P/E ratio?

View Dyne Therapeutics Inc.'s valuation metrics on Alpha Lenz.

Dyne Therapeutics Inc.

NASDAQ · DYN
$18.07-0.66(-3.52%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Dyne Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Dyne Therapeutics Inc.'s ROE is -55.7%. Explore profitability and growth together.

Ask for details

Company Overview

Dyne Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for patients with genetically-driven muscle diseases. The organization is committed to addressing unmet medical needs by enhancing muscle function and improving the quality of life for individuals suffering from disorders such as muscular dystrophies. Dyne Therapeutics employs cutting-edge technology and specialists to design precision medicine modalities, aiming for significant advancements in the field of muscle biology and therapeutics. Operating primarily within the biopharmaceutical sector, Dyne's mission is grounded in deploying its proprietary FORCE platform to deliver RNA therapies precisely to affected tissues, thereby amplifying therapeutic efficacy while minimizing off-target risks. The company's strategic research endeavors are instrumental in driving potential breakthroughs especially in disorders where current treatment options are limited or non-existent. In the broader financial market, Dyne Therapeutics Inc. contributes to the overall growth and innovation within the healthcare and biotechnology sectors. By focusing on niche areas with high demand for specialized treatments, Dyne plays a critical role in progressing the development pipeline for novel drugs, aligning with the broader goals of advancing health solutions and expanding therapeutic possibilities.

CEOMr. John G. Cox M.B.A.
SectorHealthcare
IndustryBiotechnology
Employees206

Company Statistics

FY 2025

Profile

N/AMarket Cap
$0.00Revenue
0.00Shares Out
206Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-47.52%ROA
-55.71%ROE
-46.86%ROIC

Financial Health

$893.37MCash & Cash Equivalents
$-678.54MNet Debt
22.10%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Dyne Therapeutics Inc. (ticker: DYN) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 206 employees.

The current price is $18.07 with a P/E ratio of -x and P/B of -x.

ROE is -55.71%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Dyne Therapeutics Inc. (DYN) Stock Forecast 2026 $18.07 — Price, Financials & Analyst Targets | Alpha Lenz